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Abstract Accurate and precise bilirubin and albumin
measurements are essential for proper management of
jaundiced neonates. Data hereon are lacking for Dutch
laboratories. We aimed to determine variability of measure-
ments of bilirubin and albumin concentrations typical for
(preterm) neonates. Aqueous, human serum albumin-based
samples with different concentrations of bilirubin (100, 200,
300, 400, and 500 μmol/L) and albumin (0, 10, 15, 20, 25,
and 30 g/L) were sent to laboratories of all Dutch neonatal
intensive care units (n=10). Bilirubin and albumin recoveries
of the specimens were measured using locally available routine
analytical methods. The mean, standard deviation, and
coefficients of variations (CV) were calculated per sample.
Bilirubin concentrations were underestimated in the absence of
albumin (maximal CV 26.0%). When the albumin concentra-
tion was 10 or 20 g/L, the bilirubin concentrations of the
samples were overestimated (maximal CV 14.1% and 9.2%,
respectively). Variability increased with higher weighed-in
bilirubin concentrations. Measured albumin levels were ~10%
lower than albumin levels of manufactured samples. Bilirubin
concentration did not influence albumin measurements. The
maximal CV was 6.8%. In conclusion, interlaboratory vari-
ability of bilirubin and albumin measurements is high.
Recalibration and introduction of a specific quality assessment
scheme for neonatal samples is recommended to ensure
exchangeabilityofbilirubinandalbuminmeasurementsamong
laboratories and to control the observed large variability.
Keywords Albumin.Bilirubin.Unconjugated
hyperbilirubinemia.Neonates
Introduction
The risk of severe hyperbilirubinemia and bilirubin neuro-
toxicity in newborn infants underlines the need for accurate
and precise bilirubin and albumin measurements as a part of
management guidelines for hyperbilirubinemia. To prevent
severe unconjugated hyperbilirubinemia and bilirubin neu-
rotoxicity, (inter)national guidelines are used to standardize
management of jaundiced neonates [1, 3, 11, 14]. Treatment
of unconjugated hyperbilirubinemia is based on the
measurement of total serum bilirubin (TSB) concentration.
Measurement of albumin concentration is recommended
because a low albumin concentration is considered a risk
factor for bilirubin neurotoxicity, resulting in lower TSB
treatment thresholds or albumin infusion [1].
Variability of bilirubin and albumin measurements will
obviously affect treatment decisions. In general, variability
of routine chemical parameters is controlled by quality
assessment schemes using external quality assessment
(EQA) samples. In The Netherlands, human matrix-based,
commutable EQA samples provided by the Dutch Founda-
tion for Quality Assessment in Clinical Laboratories (in
Dutch: SKML) are biweekly analyzed. However, bilirubin
and albumin concentrations of these EQA samples typically
represent adult ranges with a maximal bilirubin concentra-
tion of 80 μmol/L and a minimal albumin concentration of
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concentrations of albumin are frequently encountered in
(preterm) neonates. Data on variability of bilirubin and
albumin measurements in the neonatal range are scarce and
unavailable for Dutch laboratories [7]. In this study, we
aimed to assess variability in measurements of bilirubin and
albumin concentrations typical for neonates.
Methods
Participating laboratories
To analyze the variability of bilirubin and albumin measure-
ments,the DutchSKMLdistributed samples tolaboratoriesof
all (n=10) Dutch Neonatal Intensive Care Units (NICUs).
The NICUs were included because NICUs—and not general
hospitals—are involved in the care of preterm infants of 32
or less weeks of gestation having an increased risk of
developing hyperbilirubinemia and bilirubin neurotoxicity.
Specimens
The Dutch SKML manufactured artificial, aqueous,
albumin-based EQA samples to evaluate bilirubin and
albumin assay performance in the neonatal concentration
range. In a Tris–HCl buffer (pH 7.4) with 9 g/L NaCl,
human serum albumin (HSA) (Sigma A 1653) was
dissolved to achieve albumin concentrations ranging from
0 to 30 g/L (0, 10, 15, 20, 25, and 30 g/L). Unconjugated
bilirubin (Sigma B4146) was dissolved (protected from
light) and added to the albumin solutions immediately after
complete solution. Bilirubin concentrations ranged from
100 to 500 μmol/L (100, 200, 300, 400, and 500 μmol/L).
Table 1 shows the combinations of bilirubin and albumin
concentrations in the samples. After manufacture, the
samples were frozen below −70°C, shipped on dry ice to
the participating laboratories, and stored frozen until
analysis. All EQA samples were analyzed in April 2008.
Analytical devices
In the clinical chemistry laboratories of the corresponding
NICUs (n=10), bilirubin and albumin recoveries of the
processed EQA samples were evaluated using locally
available routine analytical methods. Measurements on point
of care analyzers were not included. All routine methods
were standardized according to the instructions of the
manufacturers. All laboratories participate in the regular
EQA program of the SKML with maximal bilirubin concen-
trations of 80 μmol/L and minimal albumin concentrations of
30 g/L, enabling them to monitor and control albumin and
bilirubin performance in the normal and slightly abnormal
concentration ranges. The majority of the samples was
measured in triplicate; a minority (one center) in duplicate.
Statistical analysis
The weighed-in concentrations of bilirubin and albumin in
the processed EQA samples were compared with the
measured concentrations as recovered by the clinical
chemistry laboratory using routine methods. The mean,
standard deviation (SD), range, and coefficients of variation
(CV) were calculated per measured sample using Microsoft
Office Excel (Microsoft Corporation, Redmond, WA, USA)
and SPSS for Windows (version 16.0, Chicago, IL, USA).
Results
Analyzers and methods
Bilirubin and albumin measurements in the NICU labora-
tories were performed with locally available analytical
methods, applied on routine clinical chemistry analyzers.
Table 2 shows the analytical devices and corresponding
methods used in the NICU laboratories.
Bilirubin
Panels a, b, and c of Fig. 1 show the measured versus the
weighed-in bilirubin concentrations in samples with albumin
concentrations of 0, 10, and 20 g/L, respectively. Underes-
timation of bilirubin concentrations occurred in the absence
of albumin (Fig. 1a). When the albumin concentration was
10 or 20 g/L (Fig. 1b, c), the bilirubin concentrations of the
samples were overestimated. Independent of the albumin
concentration in the sample, a large interlaboratory vari-
Table 1 Combinations of albumin and bilirubin concentrations in manufactured EQA samples
Sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Albumin (g/L) 0 0 0 0 0 10 10 10 10 10 10 15 20 20 20 20 20 20 25 30
Bilirubin (μmol/L) 0 100 200 300 400 0 100 200 300 400 500 0 0 100 200 300 400 500 0 0
17.1 μmol/L=1 mg/dL bilirubin
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Devices used for bilirubin measurement
Roche Modular DPD 6
Reichert Unistat bilirubinometer
a Spectrophotometric 1
Bilimeter 3
b Spectrophotometric 1
Beckman Coulter Jendrassik Grof 1
Abbot Aeroset Jendrassik Grof 1
Devices used for albumin measurement
Roche Modular 7
P800 module Bromcresol green 6
Automatic Bromcresol purple 1
Beckman Coulter 2
Synchron Lx20 Bromcresol green 1
DxC 800 Bromcresol purple 1
Abbott Aeroset Bromcresol purple 1
Table 2 Analytical devices and
methods used in Dutch NICU
laboratories
DPD: 2,5-DiCl-phenyl
diazonium
aUnistad Salm and Kipp BV
bPfaff Technik & Medizin
A: albumin = 0 g/L
B: albumin = 10 g/L
500 
400 
300 
200 
100 
Measured 
bilirubin 
(µmol/L) 
14.1  48.4 
12.1  39.8 
6.7  19.5 
6.8  22.0 
9.4  31.5 
CV 
(%) 
Min-max difference 
(%  manufactured 
bilirubin) 
C: albumin = 20 g/L
19.3 
24.1 
23.8 
25.8 
29.0 
Min-max difference 
(%  manufactured 
bilirubin) 
6.6  500 
7.9  400 
7.3  300 
8.1  200 
9.2  100 
CV 
(%) 
Measured 
bilirubin 
(µmol/L) 
Fig. 1 a–c Variability of bilirubin measurements. Measured versus
weighed-in bilirubin concentrations (17.1 μmol/L=1 mg/dL bilirubin)
in manufactured samples with albumin concentrations of 0, 10, and
20 g/L, respectively. The median of measured bilirubin concentration
is marked by the horizontal line in the central box. The boxes are
limited by the 25th and 75th percentile. The whiskers represent
minimum and maximum measured bilirubin concentrations. Outliers
(white circle) are depicted separately. Coefficients of variations (CV)
are shown in Fig. 1b and c as well as the difference between the
minimal and maximal measured bilirubin concentration, which is
expressed as percentage of the weighed-in bilirubin concentration
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with increasing bilirubin concentrations (Fig. 1b, c). For
example, for a bilirubin concentration of 100 μmol/L and
an albumin concentration of 10 g/L, the range in measured
bilirubin concentration was 97 to 128.5 μmol/L
(31.5 μmol/L), ~30% of the concentration in the sample
(Fig. 1b). For bilirubin concentrations with an albumin
concentration of 20 g/L, this increase in interlaboratory
variability was less (Fig. 1c). Maximal interlaboratory
coefficients of variation of measured bilirubin concentra-
tions were 26.0%, 14.1%, and 9.2% for samples with
albumin concentrations of 0, 10, and 20 g/L, respectively.
Albumin
Table 3 shows the mean measured albumin concentrations
of samples spiked with bilirubin ranging from 0 to
500 μmol/L (samples 6 to 20 in Table 1). Measured
albumin concentrations were ~10% lower than the concen-
trations of albumin dissolved in the samples. Maximal
interlaboratory CV was 6.8%. Unlike the albumin concen-
tration in the bilirubin measurements, bilirubin concentra-
tion did not affect albumin measurements. For example,
mean (±SD) measured albumin concentration of the
samples with an albumin concentration of 10 g/L and six
different bilirubin concentrations (samples 6 to 11 in
Table 1) was 8.9 (±0.6) g/L. For samples with an albumin
concentration of 20 g/L (samples 13 to 18 in Table 1), the
mean (± SD) albumin concentration was 18.0 (±0.7) g/L.
Discussion
This study demonstrates 1) a large variability of neonatal
bilirubin and albumin concentration measurements between
laboratories of Dutch NICUs potentially affecting treatment
of jaundiced newborn infants and 2) the lack of standardized
devices/methodology for neonatal bilirubin and albumin
measurements on laboratories of Dutch NICUs. Differences
in applied laboratory methodology can, theoretically, result
in interlaboratory variability. Discrepancies up to 13% of
bilirubin measurements have been observed in the past
between wet chemistry and dry chemistry analyzers using
quality control samples [2]. Even greater differences of 30%
higher results for wet versus dry bilirubin measurements in
human serum samples have been demonstrated [2]. In our
study, all laboratories used wet chemistry analyzers so the
observed and rather large interlaboratory variability is not due
to differences in wet versus dry chemistry methodology. Our
results are in agreement with data of Vreman et al., who
reported similar interlaboratory variability of bilirubin meas-
urements, applying similar methodology and/or devices [15].
Interlaboratory variability can be traced, at least in part,
to the height of the bilirubin concentration and to the use of
different matrixes (i.e., bovine versus human serum based),
as has been addressed previously [5–7, 13]. In 1982,
Schreiner et al. studied the bilirubin variability of stabilized
liquid quality control sera spiked with different concen-
trations of bilirubin. An interlaboratory variability compa-
rable with our findings was found as well as an increased
variability in the higher bilirubin concentrations [13].
Matrix effects refer to the difference in behavior of patient
samples versus processed (EQA) samples. In bilirubin
analysis, the protein content may affect the molar absorp-
tivity of the bilirubin reaction. Frequently used matrices for
preparing calibrators are human serum and human or
bovine serum albumin-based solutions. The variable and
unpredictable underestimation of conjugated bilirubin in
bovine serum renders the relationship between the actual
bilirubin content and assigned values in calibrators unreli-
able and dependent on the quality and source of the bovine
products. There is no reliable method for accurately
measuring the concentration of bilirubin in calibrators and
controls in bovine sera from commercial sources. The use
of these products compromises the accuracy of bilirubin
measurements in newborn infants. Therefore, human
instead of bovine serum should be used for preparing
bilirubin calibrators to minimize variability. In 2003, the
College of American Pathologists included in the Neonatal
Bilirubin Surveys a human serum-based sample enriched
solely with unconjugated bilirubin [6, 7]. Native human
serum is the most commutable matrix among different
laboratory methods because it mimics the entire serum
composition [6]. Yet, the use of the same matrix does not
necessarily imply minimal variability. Recently, the Dutch
Foundation for Quality Assessment in Clinical Laboratories
initiated a study with two native human serum samples
Table 3 Measured albumin concentrations
Albumin (g/L) Mean ± SD (range) CV (%)
30 27.2±1.0 (26.3–29.0) 3.5
25 22.6±0.9 (21.5–24.3) 4.0
20
a 18±0.7 (17.3–19.2) 3.7
15 13.3±0.7 (12.5–14.6) 5.3
10
a 8.9±0.6 (8.1–10.0) 6.8
Data represent the results of ten laboratories for the measured
concentrations of EQA samples 6 to 20 shown in Table 1 with
albumin concentrations ranging from 10 to 30 g/L. Results are
expressed as mean ± SD (ranges) with interlaboratory coefficients of
variation (CV) per concentration (percentage)
aAlbumin concentrations of 10 and 20 g/L describe mean albumin
concentrations of samples with six different bilirubin concentrations
980 Eur J Pediatr (2011) 170:977–982spiked with two different total bilirubin concentrations (30
and 70 μmol/L) to assess standardization of bilirubin
measurements in The Netherlands among different manu-
facturers. In analogy to our results, a large interlaboratory
variability was demonstrated [4].
Apart from the large interlaboratory variability, underes-
timation of the bilirubin concentration was observed in
albumin-free samples. This underestimation of bilirubin
concentration in the albumin-free samples is very likely a
pre-analytical problem: albumin is essential to dissolve and
stabilize bilirubin.
This study illustrates significant interlaboratory differences
among bilirubin measurements using aqueous HSA-based
samples.Yet,oneshouldbecarefulwithextrapolationofthese
findings to native neonatal samples as aqueous HSA-based
samples behave differently. Moreover, the variability was
deducedfromtheweighed-incalculatedbilirubinandalbumin
concentration and not by value assignment using an interna-
tionally recognized reference method. Notwithstanding these
limitations, a large interlaboratory variability of bilirubin and
albumin measurements is noticed.
International management guidelines of infants with
unconjugated hyperbilirubinemia are based on total serum
bilirubin (TSB). However, bilirubin neurotoxicity may be
better predicted by the unbound or free bilirubin, i.e., the
fraction of bilirubin not bound to plasma proteins (mainly
albumin), than by TSB. Unfortunately, free bilirubin
measurements are laborious and not routinely available, in
contrast to TSB measurements [16]. Inaccurate and/or
imprecise bilirubin measurements can potentially result in
overtreatment or undertreatment of jaundiced neonates,
including inappropriate blood sampling. Overtreatment
exposes the newborn infants to unnecessary risks. Photo-
therapy, although generally considered safe, may result in
retinal damage (when eyes are unprotected from photo-
therapylight), skin pathology, and an increased insensible
water loss [9]. Exchange transfusions are invasive and
associated with considerable morbidity and mortality (esti-
matedtooccurin50and3per1,000procedures,respectively)
[1, 10]. In contrast, underestimation of bilirubin levels may
result in undertreatment, possibly contributing to a re-
emergence of bilirubin neurotoxicity in jaundiced infants [8].
Variability of bilirubin and albumin measurements will
for obvious reasons negatively influence standardizing care
for jaundiced newborn infants. Standardized care based on
the best available evidence has been demonstrated to
improve pediatric and adult patient outcomes [12]. To
standardize the management of unconjugated hyperbiliru-
binemia, accurate and precise measurements of bilirubin
and albumin concentrations are inevitably. Monitoring
laboratory performance is of key importance herein as has
also been internationally recognized [7].
Recommendations to improve and standardize care of
jaundiced newborn infants are, according to the authors of this
study, twofold. First, accuracy of bilirubin and albumin
measurements needs to be improved and the desired quality
specifications should be defined. In agreement with interna-
tionalexperts,werecommendatotalerrorforneonatalbilirubin
of maximal 10% of the reference method [7]. Interestingly, two
manufacturers advocated to recalibrate their bilirubin assays
for measurement of total bilirubin in the last quarter of 2008.
A downscaling of formerly assigned concentrations to
calibrators of −11% to −20% was recommended [4]. Second,
commutable external quality control samples with high
neonatalbilirubinlevelsshouldbeusedtomonitortherequired
reduction in interlaboratory variability. Although originally
recommendedinthetwentiethcentury,thisrecommendationis
currently still valid for many countries [15]. In The Nether-
lands, in addition to “adult range” bilirubin and albumin
samples, bilirubin and albumin concentrations typically
encountered in jaundiced neonates, i.e., 200–500 μmol/L
and 15–25 g/L, respectively, are nowadays biweekly moni-
tored by clinical chemistry laboratories involved in the care
for neonates with unconjugated hyperbilirubinemia.
Conclusions
To comply with international guidelines for the manage-
ment of neonates with unconjugated hyperbilirubinemia,
exchangeability of bilirubin and albumin measurements
among laboratories is essential. Our current findings,
although in aqueous HSA samples, apparently point to
unacceptably high (interlaboratory) variability of bilirubin
and albumin measurements. To analyze and improve the
interlaboratory variability, a tailor-made quality assessment
scheme for neonatal samples (human serum based) is
available in The Netherlands since January 2010.
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